Wednesday, November 23, 2016

BRIEF-Lilly to abandon Alzheimer's drug after late-stage failure

* Lilly announces top-line results of solanezumab phase 3

clinical trial

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)